Penicillamine

CHEMBL1430 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
149.2 g/mol
LogP
-1.8
Phase
4

This medication treats rheumatoid arthritis, Wilson's disease, and cystinuria by binding and removing harmful substances.

الوزن الجزيئي

149,2100 g/mol

LogP

-1,80

TPSA

64,30 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)(S)[C@@H](N)C(=O)O

InChI

InChI=1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1

Molecular Formula

C5H11NO2S

HBD / HBA

3 / 4

الروابط القابلة للدوران

2

الذرات الثقيلة

9

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This medication treats rheumatoid arthritis, Wilson's disease, and cystinuria by binding and removing harmful substances.

Yes, Penicillamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1430. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5852. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.